학술논문

ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension

Document Type

Article

Author

Vermeire, S.; Sands, B.E.; Tilg, H.; Tulassay, Z.; Kempinski, R.; Danese, S.; Bunganič, I.; Nitcheu, J.; Santo, J.; Scherrer, D.; Biguenet, S.; Ehrlich, H.J.; Steens, J.-M.; Gineste, P.; Sandborn, W.J.

Source

In: The Lancet Gastroenterology and Hepatology. (The Lancet Gastroenterology and Hepatology, November 2022, 7(11):1024-1035)

Subject

Language

English

ISSN

24681253

Online Access

Full Text (ScienceDirect 종량제) Web of Science JCR 저널정보 Scopus Find it@PNU

이메일

부산대학교 도서관

Online Access

메일 발송